Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder.

This is an international multicentre study aimed at evaluating the combined value of dopaminergic neuroimaging and clinical features in predicting future phenoconversion of idiopathic REM sleep behaviour (iRBD) subjects to overt synucleinopathy. Nine centres sent 123I-FP-CIT-SPECT data of 344 iRBD patients and 256 controls for centralized analysis. 123I-FP-CIT-SPECT images were semiquantified using DaTQUANTTM, obtaining putamen and caudate specific to non-displaceable binding ratios (SBRs). The following clinical variables were also analysed: (i) Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale, motor section score; (ii) Mini-Mental State Examination score; (iii) constipation; and (iv) hyposmia. Kaplan-Meier survival analysis was performed to estimate conversion risk. Hazard ratios for each variable were calculated with Cox regression. A generalized logistic regression model was applied to identify the best combination of risk factors. Bayesian classifier was used to identify the baseline features predicting phenoconversion to parkinsonism or dementia. After quality check of the data, 263 iRBD patients (67.6 ± 7.3 years, 229 males) and 243 control subjects (67.2 ± 10.1 years, 110 males) were analysed. Fifty-two (20%) patients developed a synucleinopathy after average follow-up of 2 years. The best combination of risk factors was putamen dopaminergic dysfunction of the most affected hemisphere on imaging, defined as the lower value between either putamina (P < 0.000001), constipation, (P < 0.000001) and age over 70 years (P = 0.0002). Combined features obtained from the generalized logistic regression achieved a hazard ratio of 5.71 (95% confidence interval 2.85-11.43). Bayesian classifier suggested that patients with higher Mini-Mental State Examination score and lower caudate SBR asymmetry were more likely to develop parkinsonism, while patients with the opposite pattern were more likely to develop dementia. This study shows that iRBD patients older than 70 with constipation and reduced nigro-putaminal dopaminergic function are at high risk of short-term phenoconversion to an overt synucleinopathy, providing an effective stratification approach for future neuroprotective trials. Moreover, we provide cut-off values for the significant predictors of phenoconversion to be used in single subjects.

[1]  Alan J. Thomas,et al.  Research criteria for the diagnosis of prodromal dementia with Lewy bodies , 2020, Neurology.

[2]  B. Boeve,et al.  Confirmation of 123I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders , 2020, The Journal of Nuclear Medicine.

[3]  A. Chincarini,et al.  The fate of patients with REM sleep behavior disorder and mild cognitive impairment. , 2020, Sleep medicine.

[4]  Yves Dauvilliers,et al.  Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study , 2019, Brain : a journal of neurology.

[5]  Laura Verga,et al.  The risk of neurodegeneration in REM sleep behavior disorder: A systematic review and meta-analysis of longitudinal studies. , 2019, Sleep medicine reviews.

[6]  A. Chincarini,et al.  Presynaptic dopaminergic neuroimaging in REM sleep behavior disorder: A systematic review and meta-analysis. , 2018, Sleep medicine reviews.

[7]  H. Berendse,et al.  Lower 123I-FP-CIT binding to the striatal dopamine transporter, but not to the extrastriatal serotonin transporter, in Parkinson's disease compared with dementia with Lewy bodies , 2018, NeuroImage: Clinical.

[8]  R. Postuma,et al.  How does dementia with Lewy bodies start? prodromal cognitive changes in REM sleep behavior disorder , 2017, Annals of neurology.

[9]  E. Tolosa,et al.  Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder , 2017, Annals of neurology.

[10]  Ian A. Watson,et al.  Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis , 2017, Clinical and translational science.

[11]  Alan J. Thomas,et al.  Diagnosis and management of dementia with Lewy bodies , 2017, Neurology.

[12]  Shengdi Chen,et al.  Predictive markers for early conversion of iRBD to neurodegenerative synucleinopathy diseases , 2017, Neurology.

[13]  H. Shill,et al.  Simplified conversion method for unified Parkinson's disease rating scale motor examinations , 2015, Movement disorders : official journal of the Movement Disorder Society.

[14]  Günther Deuschl,et al.  MDS research criteria for prodromal Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[15]  G. Deuschl,et al.  MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[16]  J. Trojanowski,et al.  Conversion between Mini‐Mental State Examination, Montreal Cognitive Assessment, and Dementia Rating Scale‐2 scores in Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.

[17]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[18]  H. Vankova Mini Mental State , 2010 .

[19]  Koen Van Laere,et al.  EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2 , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  F. Nobili,et al.  Cognitive‐nigrostriatal relationships in de novo, drug‐naïve Parkinson's disease patients: A [I‐123]FP‐CIT SPECT study , 2010, Movement disorders : official journal of the Movement Disorder Society.

[21]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan , 2007, Movement disorders : official journal of the Movement Disorder Society.

[22]  R. M. Costanzo,et al.  Cross-cultural comparison of data using the odor stick identification test for Japanese (OSIT-J). , 2006, Chemical senses.

[23]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[24]  Johan Marinus,et al.  Assessment of autonomic dysfunction in Parkinson's disease: The SCOPA‐AUT , 2004, Movement disorders : official journal of the Movement Disorder Society.

[25]  I. McKeith,et al.  Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease , 2004, Neurology.

[26]  H. Briner,et al.  Smell diskettes as screening test of olfaction. , 1999, Rhinology.

[27]  T. Hummel,et al.  'Sniffin' sticks': olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. , 1997, Chemical senses.

[28]  R. Doty,et al.  Development of the university of pennsylvania smell identification test: A standardized microencapsulated test of olfactory function , 1984, Physiology & Behavior.

[29]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[30]  Y. Ben-Shlomo,et al.  The influence of age and gender on motor and non-motor features of early Parkinson's disease: initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. , 2014, Parkinsonism & related disorders.

[31]  J. Ibrahim,et al.  Handbook of survival analysis , 2014 .

[32]  L. Freedman Tables of the number of patients required in clinical trials using the logrank test. , 1982, Statistics in medicine.